Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)

BACKGROUND: Bevacizumab-awwb (MVASI(®)) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin(®) (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ran, Ogbomo, Adesuwa S., Accortt, Neil A., Lal, Lincy S., Bishi, Geetanjali, Sandschafer, Darcie, Goldschmidt, Jerome H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288425/
https://www.ncbi.nlm.nih.gov/pubmed/37360769
http://dx.doi.org/10.1177/17588359231182386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288425/
https://www.ncbi.nlm.nih.gov/pubmed/37360769
http://dx.doi.org/10.1177/17588359231182386

Ejemplares similares